FIRST LINE 5-FU-BASED CHEMOTHERAPY WITH/WITHOUT BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER: TISSUE BIOMARKER CANDIDATES

• Үндсэн зохиолчид: Assia Konsoulova (Зохиогч), Ivan Donev (Зохиогч), Nikolay Conev (Зохиогч), Sonya Draganova (Зохиогч), Nadezhda Petrova (Зохиогч), Eleonora Dimitrova (Зохиогч), Hristo Popov (Зохиогч), Kameliya Bratoeva (Зохиогч), Petar Ghenev (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Peytchinski Publishing, 2016-03-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Purpose: Colorectal cancer is the second leading cause of cancer mortality in the USA. According to Bulgarian National Statistics Institute, 2370 colon and 1664 rectal cancer cases were diagnosed in 2012 with total number of patients 29995. Adding bevacizumab to chemotherapy in patients with metasta...